Table of Content

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Dynamics
4.1. Market Overview
4.2. Drivers
4.2.1. Government Initiatives Supporting Africa’s Healthcare Sector
4.2.2. Rising Prevalence of Communicable and Non-communicable Diseases
4.2.3. Key Market Players’ Increasing Investments in Africa’s IVD Sector
4.3. Restraints
4.3.1. High Prices of IVD Products
4.4. Opportunities
4.4.1. Increasing Awareness Regarding the Importance of Early Diagnosis
4.5. Challenges
4.5.1. Uneven Access To Healthcare
4.5.2. Shortage of Trained Healthcare Personnel

5. Africa IVD Market Assessment–by Product Category
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments
5.4. Software & Services

6. Africa IVD Market Assessment–by Technology
6.1. Overview
6.2. Molecular Diagnostics
6.3. Point-Of-Care Diagnostics
6.4. Immunoassay/Immunochemistry
6.5. Biochemistry/Clinical Chemistry
6.6. Whole Blood Glucose Monitoring
6.7. Hematology
6.8. Microbiology
6.9. Coagulation & Hemostasis
6.10. Other IVD Technologies

7. Africa IVD Market Assessment–by Application
7.1. Overview
7.2. Infectious Diseases
7.3. Oncology
7.4. Diabetes
7.5. Cardiology
7.6. Nephrology
7.7. Autoimmune Disorders
7.8. Other Applications

8. Africa IVD Market Assessment–by Diagnostic Approach
8.1. Overview
8.2. Lab Testing
8.3. Point-of-care Testing
8.4. OTC/Self-Testing

9. Africa In Vitro Diagnostics Market Assessment?by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Home Healthcare
9.5. Other End Users

10. Africa IVD Market Assessment–by Geography
10.1. Overview
10.2. South Africa
10.3. Egypt
10.4. Algeria
10.5. Nigeria
10.6. Morocco
10.7. Kenya
10.8. Tunisia
10.9. Tanzania
10.10. Rest of Africa

11. Competitive Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Market Share Analysis (2022)
11.3.1. F. Hoffmann-La Roche Ltd (Switzerland)
11.3.2. Abbott Laboratories (U.S.)
11.3.3. Danaher Corporation (U.S.)

12. Company Profiles (Company Overview, SWOT Analysis for the Top 5 Companies, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Abbott Laboratories
12.2. Becton, Dickinson and Company
12.3. bioM?rieux SA
12.4. Danaher Corporation
12.5. F. Hoffmann-La Roche Ltd.
12.6. QIAGEN N.V.
12.7. Siemens Healthineers AG (A Subsidiary of Siemens AG)
12.8. Thermo Fisher Scientific, Inc.
12.9. Bio-Rad Laboratories, Inc.
12.10. Illumina, Inc.
12.11. Shenzhen Mindray Bio-Medical Electronics Co., Ltd

13. Appendix
13.1. Available Customization
13.2. Related Reports



List of Figures

List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Africa IVD Market, by Product Category, 2023 Vs. 2030 (USD Million)
Figure 8 Africa IVD Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Africa IVD Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Africa IVD Market, by Diagnostic Approach, 2023 Vs. 2030 (USD Million)
Figure 11 Africa IVD Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Africa IVD Market, by Country/Region
Figure 13 Market Dynamics
Figure 14 Africa IVD Market, by Product Category, 2023 Vs. 2030 (USD Million)
Figure 15 Africa IVD Market, by Technology, 2023 Vs 2030 (USD Million)
Figure 16 Adult Population (20–79 Years) with Diabetes in African Countries (Millions)
Figure 17 Africa IVD Market, by Application, 2023 Vs 2030 (USD Million)
Figure 18 Number of HIV Cases Vs HIV/AIDS Deaths in African Countries (2020)
Figure 19 Africa IVD Market, by Diagnostic Approach, 2023 Vs 2030 (USD Million)
Figure 20 Africa In Vitro Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 21 Africa: Number of People (Aged 20–79 Years) with Diabetes (In Millions), 2021–2045
Figure 22 Africa IVD Market, by Snapshot
Figure 23 South Africa: Number of People (All Ages) Living with HIV (2010–2020)
Figure 24 South Africa: Number of People with Diabetes (In Thousands), 2000–2045
Figure 25 Algeria: Population Aged 65 and Above (2015–2021)
Figure 26 Algeria: People Aged 20-79 Years Suffering from Diabetes (2011–2045) (In Thousand)
Figure 27 Nigeria: Number of Pmi-Supported Health Facilities (2016–2020)
Figure 28 Morocco: Number of New Cancer Cases: 2020-2030
Figure 29 Share of People Living in Urban Areas: 2015–2020
Figure 30 Public Expenditure On Healthcare as Percent of Total Healthcare Expenditure: 2015–2021
Figure 31 Tanzania: Number of People with HIV (2010–2020)
Figure 32 Tanzania: Number of Adults (20–79 Years) with Diabetes (2011–2021)
Figure 33 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 34 Africa IVD Market: Competitive Benchmarking
Figure 35 Market Share Analysis: Africa IVD Industry (2022)
Figure 36 Abbott Laboratories: Financial Overview (2022)
Figure 37 Becton, Dickinson and Company: Financial Overview (2022)
Figure 38 bioM?rieux SA: Financial Overview (2022)
Figure 39 Danaher Corporation: Financial Overview (2022)
Figure 40 F. Hoffmann-La Roche Ltd.: Financial Overview (2022)
Figure 41 QIAGEN N.V.: Financial Overview
Figure 42 Siemens Healthineers AG: Financial Overview (2022)
Figure 43 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 44 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
Figure 45 Illumina, Inc.: Financial Overview (2022)
Figure 46 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2022)